# A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT06944496** · PHASE3 · NOT_YET_RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 616 (estimated)

## Conditions studied

- Gastric Carcinoma

## Interventions

- **BIOLOGICAL:** Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine
- **BIOLOGICAL:** Tislelizumab+Oxaliplatin+Capecitabine

## Key facts

- **NCT ID:** NCT06944496
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2028-05-15
- **Final completion:** 2030-05-15
- **Target enrollment:** 616 (ESTIMATED)
- **Last updated:** 2025-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06944496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06944496, "A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06944496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*